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Rhodococcus equi is an opportunistic pathogen that usually causes infection in immuno-
compromised hosts. A heart transplant recipient who had been treated with amphoter-
icin B for pulmonary aspergillosis showed newly developed multiple nodules with a
central necrotic area in the right lower lobes. Cultures of several blood samples and an
aspirate of the lung nodule yielded a Gram-positive coccobacillary bacterium, which was
initially reported as a Corynebacterium species, but was later identiﬁed as R. equi by API
CORYNE (bioMerieux SA, Marcy l’Etoile, France) and by demonstrating the production
of ‘equi factor’. The identiﬁcation was subsequently conﬁrmed by an R. equi-speciﬁc
polymerase chain reaction (PCR). The patient was successfully treated with ciproﬂoxacin
and azithromycin for 14weeks. This is the ﬁrst documented case of R. equi infection in
Korea. There is a possibility of underestimation of R. equi infections due to the mis-
identiﬁcation of the organism as a contaminating diphtheroid. Because R. equi will not
respond to the conventional empirical therapy, the microbiology laboratory should
identify R. equi in a timely manner. R. equi-speciﬁc PCR will be a useful conﬁrmatory
test in human infection.
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Rhodococcus equi is an aerobic, facultatively intra-
cellular, Gram-positive coccobacillus and is
usually present in soil and the feces of horses
[1]. With the increase in HIV infection and organ
transplantation, the organism has been emerging
as an important opportunistic pathogen in immu-
nocompromised patients [2]. We report a case of R.
equi pneumonia in a heart transplant recipient.
This is the ﬁrst reported case of R. equi infection
in Korea.
A 48-year-old man with cardiac sarcoidosis
underwent heart transplantation in January 2000,
and thereafter had an uneventful 8months,
with maintenance immunosuppressive therapy
consisting of cyclosporine (225mg/day), myco-
phenolate mofetil (2.0 g/day), and prednisone
(12.5mg/day). Because of decreased right ventri-
cular (RV) contractility and a newly developed
tricuspid regurgitation, the dose of prednisone
was increased to 30mg daily. After 1month, RV
contractility improved, but 1week later the patient
was admitted because of a positive cytomegalo-
virus (CMV) antigenemia test. Despite pre-emp-
tive gancyclovir treatment, CMV antigenemia was
sustained for 14weeks, with a ﬂuctuation of posi-
tive cell counts. After 7 days in hospital, the patient
was diagnosed as having cryptococcal meningitis
and was treated with liposomal amphotericin B.
The cyclosporine dose was reduced to 175mg
daily, and mycophenolate was discontinued,
while intravenous dexamethasone was given for
3 weeks to control the increased intracranial pres-
sure. After the administration of 2.5 g of liposomal
amphotericin B for 3weeks, it was replaced with
oral ﬂuconazole. One week later, a chest radio-
graph showed consolidation and parapneumonic
effusion in the right lung ﬁeld. Percutaneous nee-
dle aspirates of the right lung conﬁrmed invasive
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pulmonary aspergillosis. Liposomal amphotericin
B was administered again, up to 3.5 g for 4 weeks,
and was replaced with oral ﬂuconazole. After
2months of hospitalization, famcyclovir (750mg
daily) was administered for 7 days for a varicella
zoster infection. On the 63rd hospital day, after
4weeks of amphotericin B for aspergillosis, the
patient showed a mild fever of up to 38.5 8C and
had right upper quadrant pain. In three sets of
blood cultures, a Gram-positive coryneform bacil-
lus grew in aerobic vials only. RapID CB Plus
(Innovative Diagnostic System, Norcross, GA,
USA) failed to identify it. It was reported as a
Corynebacterium species, and the clinicians dis-
missed it as a contaminant. Because fever and pain
continued in spite of the antifungal treatment,
three further sets of blood cultures were drawn
6 days later. All aerobic vials grew the same Gram-
positive bacilli again. A chest CT scan performed
on the 78th hospital day showed newly developed
multiple nodules with a central necrotic area in the
right lower lobes. The central necrotic portion of
the lung nodules was aspirated with a CT scan
guide on the 80th hospital day. A direct smear of
the aspirate showed the same Gram-positive
bacilli that grew repeatedly from the blood sam-
ples taken in the previous weeks.
The Gram-positive coryneform organism was
non-motile, non-fermentative, positive for cata-
lase, urease, and nitrate reduction, and negative
for oxidase and indole. After 48 h of incubation on
sheep blood agar plates, the colonies were non-
hemolytic, irregularly round, mucoid and pale
pink, and a Gram stain revealed Gram-positive
coccobacilli. After a 6-h incubation on brain–heart
infusion agar at 35 8C, these microorganisms were
completely bacillary (Figure 1A), but they became
totally coccoid 24 h later (Figure 1B). With API
CORYNE (bioMe´rieux SA, Marcy l’Etoile, France),
the microorganism was identiﬁed as a Rhodococcus
species. We conﬁrmed the production of so-called
‘equi factors’ by a CAMP test. The modiﬁed Kin-
yon stain failed to show acid fastness. To conﬁrm
the identiﬁcation of R. equi, a polymerase chain
reaction (PCR) using primers for R. equi-speciﬁc
16S rRNA was carried out as previously described
[3,4]. Primer sequences were as follows: 16S for-
ward, TCGTCCGTGAAAACTTGGG; and 16S
reverse, CGACCACAAGGGGGCCGT. The
441-bp product was ampliﬁed from the patient
isolate and an R. equi strain received from the
College of American Pathologists (Figure 2). An
Figure 1 Microscopic morphology. The bacillary form
after a 6-h incubation (A) was changed to a completely
coccoid form after 24 h (B) (Gram stain, 1000).
Figure 2 Agarose gel electrophoresis of 441-bp amplified
products by PCR using 16S rRNA primers specific for
Rhodococcus equi. Lanes: 1, no template DNA as a negative
control; 2, R.equi strain from CAP survey as a positive con-
trol; 3, the patient isolate; 4,Staphylococcus aureusATCC25923
as a negative control; M, DNA size marker (1-kb ladder).
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antimicrobial susceptibility test was performed by
the disk diffusionmethod onMueller–Hinton agar
supplemented with 5% sheep blood. Based on the
National Committee for Clinical Laboratory Stan-
dards criteria for streptococci other than Strepto-
coccus pneumoniae [5,6], the microorganism was
resistant to penicillin, ampicillin, cefazolin, and
clindamycin, and susceptible to vancomycin, ami-
kacin, erythromycin, azithromycin, imipenem,
and ciproﬂoxacin.
After 12 days of treatment with vancomycin
(1000mg/day), based on susceptibility results,
treatment with ciproﬂoxacin (800mg/day intrave-
nously followed by 500mg twice daily orally) and
azithromycin (250mg/day orally) was started.
Because of the rhodococcus infection, the doses
of cyclosporine and prednisone were reduced to
100mg and 10mg, respectively. The fever sub-
sided and the nodules decreased radiologically
during the 4weeks of therapy. The patient was
discharged on oral ciproﬂoxacin (500mg twice
daily by mouth) and azithromycin (250mg/day
by mouth). He was readmitted 6weeks later be-
cause a follow-up chest radiograph showed a
slight increase in the size of the nodules. After
4weeks of treatment with intravenous ciproﬂox-
acin (800mg/day), the size of the nodules decreas-
ed progressively, and the patient was discharged
on oral ciproﬂoxacin (750mg twice daily) and
clarithromycin (500mg twice daily).
AIDS is a predominant underlying condition in
rhodococcus infection, but solid organ transplant
recipients are also affected by R. equi. Of all the
published reports of R. equi infection in humans,
transplant recipients account for almost 10% of the
cases [7]. Because the immunosuppressive effects
of CMV infection in solid organ transplantation
have been postulated as predisposing factors for
various opportunistic infections [8], a longstand-
ing CMV infection can contribute to further infec-
tions. The lung is the organ most frequently
affected byR. equi [1]. As in our case, the radiologic
features frequently consist of nodules localized in
one lobe. Localized nodules are also associated
with tuberculosis or a fungal infection. Although
the bacteremia rate has been reported to be very
low in transplant recipients compared with AIDS
patients (25% versus 83%) [9], bacteremia was
detected ﬁrst in our case. This may be because
the lung lesions were masked by complicated
pulmonary aspergillosis until they had advanced
to nodular lesions with necrosis.
In this case, the identiﬁcation of R. equi took 3
weeks from the time at which the organism was
ﬁrst isolated from a blood culture, and initially it
was reported as a Corynebacterium species. The
microscopic ﬁnding may cause confusion with
non-pathogenic Gram-positive diphtheroids that
are usually considered contaminants. Moreover,
because this organism is a relatively inactive non-
fermenter, most commercial identiﬁcation kits are
not able to identify R. equi reliably. Although
modiﬁed acid-fast stains of direct smears or young
colonies may be helpful in cases of suspected R.
equi infection, acid-fast stains are rarely positive in
older and subcultured colonies, as in this case. In
contrast, a misinterpretation of acid-fast forms
may result in a treatment for mycobacterial infec-
tion in the clinical setting of a patient with fever
and a cavitary lung lesion [9], particularly in areas
where tuberculosis is prevalent, as in Korea.
Recently, ampliﬁcation of R. equi-speciﬁc chromo-
somal DNA has been proved to be sensitive and
speciﬁc for R. equi pneumonia in foals [4]. It will be
useful for rapid and accurate diagnosis of R. equi in
cultures or clinical specimens where R. equi is
rarely found.
As in our case, R. equi is typically susceptible to
macrolides, rifampin, ciproﬂoxacin, aminoglyco-
sides, and glycopeptides. However, the lung lesion
and fever did not respond to vancomycin therapy,
and the lesion increased again after the initial
favorable response to ciproﬂoxacin and azithro-
mycin. A considerable number of R. equi infections
result in relapse, and the mortality rate is high in
spite of treatment with drugs to which R. equi is
susceptible, because intracellular concentrations of
the drugs are critical to kill intraphagocytic forms
of R. equi [1]. For this reason, drugs with high
intracellular concentrations, such as macrolides,
quinolones, and rifampin, should be considered
for the treatment of R. equi infection [1,9,10]. In
addition, control of predisposing factors, such as
a decrease in the dose of immunosuppressive
drugs or control of underlying malignancies, is
recommended [9]. R. equi infection is less often
fatal in recipients of solid transplants than in
AIDS patients, because the degree of immunosup-
pression can be reduced, as it was in our case
[9,11,12].
With the increase in HIV infection and organ
transplantation in Korea, the microbiology labora-
tories need a greater awareness of R. equi infec-
tions. Because R. equi infection may not respond to
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empirical antimicrobial treatment, R. equi should
be identiﬁed in a timely manner. PCR is a rapid,
sensitive and speciﬁc diagnostic test for R. equi in
human infections.
REFERENCES
1. Verville TD, Huycke MM, Greenfield RA, Fine DP,
Kulhs TL, Slater LN. Rhodococcus equi infection of
humans: 12 cases and a review of literature.
Medicine 1994; 73: 119–32.
2. Prescott JF. Rhodococcus equi: an animal and human
pathogen. Clin Microbiol Rev 1991; 4: 20–34.
3. Sellon DC, Walker K, Suyemoto M, Altier C.
Nucleic acid amplification for rapid detection of
Rhodococcus equi in equine blood and tracheal wash
fluids. Am J Vet Res 1997; 58: 1232–7.
4. Sellon DC, Besser TE, Vivrette SL, McConnico RS.
Comparison of nucleic acid amplification, serology
and microbiologic culture for diagnosis of Rhodo-
coccus equi pneumonia in foals. J Clin Microbiol 2001;
39: 1289–93.
5. National Committee for Clinical Laboratory Stan-
dards. Performance standards for antimicrobial disk
susceptibility tests, 7th edn. Approved standard M2-
A7. Wayne, PA: NCCLS, 2000.
6. Weiss K, Laverdiere M, Rivest R. Comparison of
antimicrobial susceptibilities of Corynebacterium
species by broth microdilution and disk diffusion
methods.AntimicrobAgentsChemother 1996; 40: 930–3.
7. Scott MA, Graham BS, Verrall R, Dixon R, Schaffner
W, Tham KT. Rhodococcus equi—an increasingly
recognized opportunistic pathogen. Am J Clin Pathol
1995; 103: 549–55.
8. Paya CV. Indirect effects of CMV in the solid organ
transplant patient. Transplant Infect Dis 1999;
1(suppl 1): 8–12.
9. Mun˜oz P, Burillo A, Palomo J, Rodrı´guez-Cre´ixems
M, Bouza E. Rhodococcus equi infection in transplant
recipients. Transplant 1998; 65: 449–53.
10. Capdevila J, Bujan S, Gavalda J, Ferrer A, Pahissa
A. Rhodococcus equi pneumonia in patients infected
with human deficiency virus: report of 2 cases
and review of literature. Scand J Infect Dis 1997; 29:
535–41.
11. Lnasky JA, Pulingham N, Powers MA, Durack
D. Rhodococcus equi causing human pulmonary
infection: review of 29 cases. South Med J 1991; 84:
1217–20.
12. Barsotti M, Cupisti A, Morelli E, Meola M, Barsotti
G. Sepsis from Rhodococcus equi successfully treated
in a kidney transplant recipient. Nephrol Dial
Transplant 1997; 12: 2002–4.
 2003 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 9, 230–233
Concise Communication 233
